If you walk into a vape shop in Texas tomorrow and buy a brightly colored disposable in some fruit flavor, you are almost certainly buying a product the FDA has never authorized. That is not a secret or a scandal. It is just the PMTA system working exactly as it does: millions of applications in, only a handful of marketing orders out, and the rest sitting in a queue the agency cannot clear. And right now, while those applications gather dust, the rulebook itself is being rewritten.
The thirty second version
Before the machinery, the headline version. The PMTA, or Premarket Tobacco Product Application, is the formal review a vape company must pass before the FDA will let it market a product in the United States. The company submits scientific data, and the agency decides whether selling the product is "appropriate for the protection of the public health." There are only three ways it ends: the FDA grants a marketing order (MGO), issues a denial (MDO), or the application sits pending. A pending PMTA is not authorization. It just means the queue has not moved yet. Here is the part that matters today: on September 28, 2026 the FDA announced it intends to reassess and possibly replace the entire PMTA framework, and on October 8 a federal judge in Texas paused a lawsuit challenging the current rule while that rethink happens. The rules are being rewritten while we speak.
How we got here: five dates that built the machine
The PMTA did not start with vaping. It started with a legal fiction about dates. Congress wrote the original Tobacco Control Act in 2009, which said any "new tobacco product" needs FDA authorization before it can be sold. A new tobacco product was defined, roughly, as anything that was not already on the American market by February 15, 2007. Cigarettes were grandfathered in. Vapes, which barely existed in 2007, were not.
| Year | What happened |
|---|---|
| 2007 | The cutoff date: products already marketed by February 15, 2007 are grandfathered; everything else is "new" |
| 2009 | Congress passes the Tobacco Control Act, giving the FDA authority over tobacco products |
| 2016 | The deeming rule extends that authority to e-cigarettes, e-liquids, and ENDS components |
| 2020 | The PMTA submission deadline: manufacturers had to file by September 9, 2020 to stay on the market during review |
| 2021 | The 2021 PMTA rule takes effect on November 4, spelling out exactly what data and records each application must contain |
One detail vapers miss: the FDA treats every device, every e-liquid flavor, and every nicotine strength as a separate product. A company selling thirty products files thirty applications. That single detail is why the numbers look the way they do.
Inside the review machine
So what actually happens after a company files? The application walks through a series of gates, and most never reach the end.
1. Acceptance. The FDA does a completeness check on the submission itself. If the paperwork is not in order, it is refused at the door and the company starts over. This is the step that later became a lawsuit: Altria's subsidiaries argued the agency effectively holds the statutory 180-day clock before even treating a submission as a complete application.
2. Filing. The agency confirms the application contains enough substance to review. The company gets a filing letter. Many applications from smaller brands died at this stage, rejected before any science was evaluated.
3. Substantive scientific review. This is the long one. Reviewers examine ingredients, manufacturing controls, toxicology, clinical and behavioral data, marketing plans, and a population health model. The central question is the APPH standard: is marketing this product appropriate for the protection of the public health? That weighs possible benefits for adult smokers against risks to non-users, especially youth.
4. The decision. One of two orders comes out. A marketing granted order (MGO) authorizes the product under the terms of the order. A marketing denial order (MDO) rejects it. There is no third door.
5. Postmarket life. Authorized products enter a world of record-keeping, reporting requirements, and advertising restrictions. The FDA has also been developing a supplemental PMTA pathway, meant to let manufacturers tweak an already-authorized product without effectively restarting the entire review from zero.
The cost of entry is brutal. Estimates from the FDA and industry put preparing a single application anywhere from $100,000 to well over $1 million, mostly scientific studies and testing. That cost is the quiet reason the authorized list looks like a roster of tobacco giants.
The verdict: MGO versus MDO
| Outcome | What the FDA decided | Legal to sell? |
|---|---|---|
| Marketing granted order (MGO) | The product meets the public health standard | Yes, under the order's terms |
| Pending / filed | Still under review, no decision yet | Not authorized; sold under enforcement discretion, and state rules differ |
| Marketing denial order (MDO) | The product failed the standard | No, unless a court intervenes |
An MDO does not always end the story. Denials have been rescinded, vacated, or stayed by courts, sending the product back to pending. That is why tracking one order number matters more than any press release.
The math that broke the system
The scale of this program is hard to overstate. The FDA received PMTAs covering more than six million products. It has authorized roughly four dozen. Think about that ratio for a moment. The authorized names belong to NJOY, Vuse, Logic, JUUL, and Glas, and nearly every one is tobacco or menthol flavored. Hundreds of other manufacturers received marketing denial orders covering more than a million products between them. The law requires the agency to grant or deny applications as promptly as possible, and in no event later than 180 days after receiving them. The FDA has never met that deadline, and some applications have waited years. The GAO backlog report put the dysfunction on the record: tens of thousands of tobacco applications were still sitting undecided, a backlog that explains why the marketplace feels so unregulated even though a whole federal review system exists.
The plot twist: three dates, one rewriting
Now the part that makes this guide different from every older PMTA explainer on the internet. The system described above may not survive in its current form.
On September 2, 2026, Altria subsidiaries Helix Innovations and NJOY, joined by the Texas Food and Fuel Association and two Texas retailers, sued in the Northern District of Texas to challenge the 2021 PMTA rule and how it has been administered. Their core argument is the clock: the statute gives the FDA 180 days to decide on an application, and the plaintiffs pointed to nicotine pouch applications that waited more than 2,200 days for a decision. They argued the agency's preliminary review dance effectively delays when the clock even starts, while unauthorized competitors fill the shelves.
On September 28, 2026, the FDA answered in a way nobody quite expected. The agency announced it intends to reassess its premarket review framework and may start new rulemaking to replace the current system. It cited its own experience with the 2021 rule, a fast-moving product market, and the widespread unauthorized market as reasons the old framework no longer fits. Crucially, it gave no timeline and released no draft rule, and said it will keep reviewing applications under the current rules in the meantime. Nothing changes for manufacturers or shoppers tomorrow.
Then on October 8, 2026, U.S. District Judge James Wesley Hendrix granted a joint request by the FDA and the plaintiffs to stay the Texas litigation while the anticipated rulemaking plays out. The parties must file joint status reports every 45 days. Even members of Congress are watching the queue: Krishnamoorthi questioned FDA about the pace of PMTA review, pressing the agency on applications that have sat undecided for years.
Put it plainly. The challengers sued over a broken clock, the agency agreed the clock needs replacing, and the judge hit pause so they can build a new one. What comes next, a proposed rule, public comment, a new framework, has no set date. For the first time in years, the PMTA story has forward motion.
At the shop counter: what PMTA status means for you
Forget the agency org charts. Here is how to read a product through PMTA-colored glasses the next time you buy.
Check the authorized list first. Fewer than fifty products have marketing orders. If yours is on it, the product went through the full review. Our breakdown of the FDA authorized list walks through every brand and flavor that made it.
Treat "PMTA pending" as a shrug, not a seal. It means the company filed paperwork. It does not mean the product passed, will pass, or is safer than anything else. Pending products often stay on shelves under the FDA's enforcement discretion, which is a priority ranking, not a green light.
"FDA approved" is almost always wrong language. The FDA does not "approve" vapes; it authorizes them via marketing orders. Packaging that claims FDA approval for a disposable is a red flag, and our guide to spotting fake vapes shows the other packaging tells worth knowing.
Denials matter at the state level too. A growing number of states run their own product registries that reference PMTA status. The federal picture and your state's registry can point in different directions, so check both before assuming a product is legal where you live.
When in doubt, stick to the short list. Authorized products are few, but they exist. The Vuse vs NJOY comparison breaks down the two biggest authorized brands head to head, if you want a legal device with a clear pedigree.
Why your favorite disposable never filed
It is worth being blunt about why the vape shop shelf looks nothing like the authorized list. First, the economics: an application costs six or seven figures, which prices out nearly every independent brand and most importers. Second, the flavors: almost every authorization granted so far covers tobacco or menthol, and the agency has denied applications for flavored products again and again, which is exactly where the disposable market lives. Third, the enforcement gap: with millions of products and a handful of reviewers, unauthorized products can operate for years under enforcement discretion, which weakens the incentive to file at all. The Texas vape ban fight shows how states are starting to fill that gap with their own rules. And if you want to see what the authorized end of the market actually looks like in a pod device, the NJOY Daily review covers one of the few products that cleared the bar.
Quick-fire answers
Does a pending PMTA mean a vape is legal? No. It means the application is under review. Selling a pending product may still violate federal law and your state's registry rules.
How long does the FDA take to decide? The statute says 180 days. In practice, years. Some applications have waited more than 2,200 days, which is exactly what the Texas lawsuit is about.
Did JUUL get PMTA authorization? Yes, for its device and Virginia tobacco and menthol pods in July 2025. Its flavored products were not authorized.
Why are so few vapes authorized? The application cost runs from $100,000 to well over $1 million, each flavor and strength needs its own application, and the scientific bar is set at population-level public health benefit.
What is a supplemental PMTA? A developing pathway that would let manufacturers make certain changes to an already-authorized product without restarting the full review process. The FDA has discussed it as part of modernizing the system.
Is the PMTA process changing? It may be. The FDA announced in September 2026 that it intends to reassess and possibly replace the framework, and the Texas lawsuit challenging the current rule is stayed while that rethink happens. No draft rule exists yet.
Can I check a specific product's status? The FDA maintains a marketing orders list, and our FDA authorized list translates it into plain English with the brands explained.
The bottom line
The PMTA was designed as a gate: scientific proof in, legal permission out. In practice it became a bottleneck, with six million applications feeding a system that authorized a few dozen products and never met its own 180-day deadline. That bottleneck is exactly why the unauthorized market exploded, and it is why the FDA is now talking about replacing the framework while a Texas judge keeps the courthouse doors open. If you are a vaper, the practical rule has not changed: authorized means reviewed, pending means uncertain, and everything else is a gamble. Keep an eye on the rulemaking. The next version of this system will decide what sits on American shelves for the next decade.